IBRX Q3 2021 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$66,000-56.3% YoY

Gross Profit

$66,000100.0% margin

Operating Income

-$79M-119448.5% margin

Net Income

-$88M-132771.2% margin

EPS (Diluted)

$-0.22

QoQ Revenue Growth

-80.5%

Cash Flow

Operating Cash Flow

-$73M

Free Cash Flow

-$81M

Stock-Based Comp.

$14M

Balance Sheet

Total Assets

$214M

Total Liabilities

$404M

Stockholders' Equity

-$188M

Cash & Equivalents

$65M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$66,000	$151,000	-56.3%
Gross Profit	$66,000	$151,000	-56.3%
Operating Income	-$79M	-$66M	-19.7%
Net Income	-$88M	-$66M	-33.6%